Publication at First Faculty of Medicine |
2003
Abstract
Five women and one man at age of 44 to 70 with relapsed or refractory Ph-positive ALL were treated within multicentre study of extended access CZSTI5710114 with imatinib (Glivec, STI 571) at the dose 600mg daily. Patients were followed-up for 454 days in median (41?597).
Haematologic response (complete in 11 (34 %) and partial in 18 (56 %) patients) was achieved in median of 28 days. At present time, imatinib represents the most powerful drug for conservative therapy of CML.
Our experience confirms its high response rate also in patients with accelerated phase of CML. Efficacy of imatinib treatment has been increased with shorter duration and less advanced disease.